Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-29 · accession 0001193125-26-033600 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-02-02 | 2026-01-29+ | BEAM | Evans John M. | CEO, Dir | S - Sale+OE | $28.87 | -50.0K | 986.7K | -5% | -$1.44M |
| DMT | 2026-02-02 | 2026-01-29+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.67 | +50.0K | 1.01M | +5% | +$33.5K |
| DT | 2026-02-02 | 2026-01-31 | BEAM | Evans John M. | CEO, Dir | A - Grant | $0.00 | +180.0K | 180.0K | New | $0 |
| DMT | 2026-02-02 | 2026-01-29+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.00 | -50.0K | 93.7K | -35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-30 | S | D | 2,906 | $29.00 | 986,667 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-30 | S | D | 22,094 | $28.27 | 989,573 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2026-01-30 | M | A | 25,000 | $0.67 | 1,011,667 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-29 | M | A | 19,336 | $0.67 | 1,006,003 | D | — | — | |
| 5 | Common | Common Stock | 2026-01-29 | M | A | 5,664 | $0.67 | 1,011,667 | D | — | — | |
| 6 | Common | Common Stock | 2026-01-29 | S | D | 16,333 | $29.19 | 995,334 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 7 | Common | Common Stock | 2026-01-29 | S | D | 8,667 | $29.74 | 986,667 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-01-31 | A | A | 180,000 | $0.00 | 180,000 | D | $27.62 · — to 2036-01-31 | 180,000 Common Stock | (F7) This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-01-30 | M | D | 25,000 | $0.00 | 68,672 | D | $0.67 · — to 2028-05-08 | 25,000 Common Stock | (F6) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-01-29 | M | D | 19,336 | $0.00 | 0 | D | $0.67 · — to 2028-05-08 | 19,336 Common Stock | (F5) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022. |
| 11 | Derivative | Stock Option (Right to Buy) | 2026-01-29 | M | D | 5,664 | $0.00 | 93,672 | D | $0.67 · — to 2028-05-08 | 5,664 Common Stock | (F6) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |